At the pre-specified interim analysis (IA; median follow-up, 17.4 months), IMbrave050 met its primary endpoint of improved independent review facility (IRF)–assessed recurrence-free survival (RFS) in patients with high-risk hepatocellular carcinoma (HCC). The RFS hazard ratio (HR) for atezolizumab plus bevacizumab vs. active surveillance was 0.72 (adjusted 95% CI 0.53–0.98; p = 0.012), and overall survival (OS) data were immature. Here, we report an updated post hoc analysis of RFS and the second IA of OS, along with additional data.
At the pre-specified interim analysis (IA; median follow-up, 17.4 months), IMbrave050 met its primary endpoint of improved independent review facility (IRF)–assessed recurrence-free survival (RFS) in patients with high-risk hepatocellular carcinoma (HCC). The RFS hazard ratio (HR) for atezolizumab plus bevacizumab vs. active surveillance was 0.72 (adjusted 95% CI 0.53–0.98; p = 0.012), and overall survival (OS) data were immature. Here, we report an updated post hoc analysis of RFS and the second IA of OS, along with additional data.